Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;63(11):3153-3157.
doi: 10.1007/s10620-018-5186-1. Epub 2018 Jul 12.

β-Blockers Improve Presinusoidal Portal Hypertension

Michael Sørensen  1 , Lars P Larsen  2 , Gerda E Villadsen  3 , Niels K Aagaard  3 , Henning Grønbæk  3 , Susanne Keiding  3 , Hendrik Vilstrup  3
Affiliations

β-Blockers Improve Presinusoidal Portal Hypertension

Michael Sørensen et al. Dig Dis Sci. 2018 Nov.

Abstract

Background: Presinusoidal portal hypertension is a clinically important cause of gastric and gastroesophageal varices. Whereas β-blockers have an established prophylactic role against bleeding from esophageal and gastric varices in portal hypertension due to cirrhosis, the effect on presinusoidal portal hypertension is unknown.

Aims: To evaluate the hemodynamic effect of β-blockers in non-cirrhotic patients with presinusoidal portal hypertension.

Methods: We measured the blood pressure gradient from spleen pulp to free hepatic vein in 12 patients with presinusoidal portal hypertension by combined hepatic vein catheterization and spleen pulp puncture while on and off β-blocker treatment (random sequence).

Results: The β-blockers reduced the gradient from a mean off-treatment value of 32 mm Hg to a on-treatment value of 26 mm Hg (P < 0.05) with a reduction of at least 20% in five patients (42%).

Conclusions: β-blocker treatment caused a clinically significant reduction in the pressure gradient from spleen pulp to the free hepatic vein. This finding supports the recommendation for prophylactic β-blockage in patients with presinusoidal portal hypertension.

Keywords: Gastroesophageal varices; Non-cirrhotic portal hypertension; Portal vein thrombosis; Propranolol; Splenic vein thrombosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflict of Interest.

Ethical Statement

For this type of study, formal consent is not required.

Figures

Fig. 1
Fig. 1
Individual pairs of blood pressure gradients from spleen pulp to free position in hepatic vein in patients with presinusoidal portal hypertension. Each subject was investigated off (left) and on (right) treatment. Mean values for the groups are represented by horizontal lines
See this image and copyright information in PMC

References

    1. Khanna R, Sarin SK. Non-cirrhotic portal hypertension—diagnosis and management. J Hepatol. 2014;60:421–441. doi: 10.1016/j.jhep.2013.08.013. - DOI - PubMed
    1. Kumar A, Sharma A, Arora A. Review article: portal vein obstruction—epidemiology, pathogenesis, natural history, prognosis and treatment. Aliement Pharmacol Ther. 2015;41:276–292. doi: 10.1111/apt.13019. - DOI - PubMed
    1. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–768. doi: 10.1016/j.jhep.2010.06.004. - DOI - PubMed
    1. Heebøll S, Villadsen GE, Aagaard NK, Grønbøk H, Vilstrup H, Keiding S. Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience. Scand J Gastroenterol. 2013;48:969–973. doi: 10.3109/00365521.2013.805811. - DOI - PubMed
    1. Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–582. doi: 10.1038/nrgastro.2009.149. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources